Pirfenidone treatment decreases transforming growth factor-β1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity

American Journal of Transplantation

Volumn 2, Issue 2, 2002, Pages 111-119

  Shihab, Fuad S ^a   Bennett, William M ^b   Yi, Hong ^a   Andoh, Takeshi F ^b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b L S Organ/Cell Transplant Serv   (United States)

Author keywords

Biglycan; Chronic nephrotoxicity; Cyclo sporine; Extracellular matrix; Fibrosis; Pirfenidone; Plasminogen activator inhibitor 1; Rats; Transforming growth factor 1

Indexed keywords

CYCLOSPORIN A; MATRIX PROTEIN; MESSENGER RNA; PIRFENIDONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY FIBROSIS; MALE; NEPHROTOXICITY; NONHUMAN; NORTHERN BLOTTING; PROTEIN EXPRESSION; RAT; SODIUM RESTRICTION; TREATMENT PLANNING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCINOSIS; CREATININE; CYCLOSPORINE; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES; MALE; PROTEOGLYCANS; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0347996179     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.020201.x     Document Type: Article

References (41)

1. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100.
2. Myers BD, Ross JC, Newton LD, Luetscher JA, Perlroth MG. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 600-705.
3. Shihab FS, Andoh TF, Tanner AM et al. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 1141-1151.
4. Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56: 2147-2159.
5. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-β1 and matrix proteins in chronic cyclosporine nephropathy. Kidney Int 1997; 52: 660-673.
6. Shihab FS, Yi H, Bennett WM, Andoh TF. Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000; 58: 1174-1185.
7. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
8. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta-1. Nature 1990; 346: 371-374.
9. Akagi Y, Isaka Y, Arai M et al. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50: 148-155.
10. Border WA, Noble NA, Yamamato T et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361-364.
11. Isaka Y, Brees DK, Ikegaya K et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418-423.
12. Isaka Y, Akagi Y, Ando Y et al. Gene therapy by transforming growth factor-β receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999; 55: 465-475.
13. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri S. Dietary intake of pirfenidone ameliorates bleomycin induced lung fibrosis in hamsters. J Lab Clin Med 1995; 125: 779-785.
14. Suga H, Teraoka S, Oka K et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxic Pathol 1995; 47: 287-292.
15. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med 1999; 159: 1061-1069.
16. Shimizu F, Fukagawa M, Yamauchi S et al. Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions. Nephrol 1997; 3: 315-322.
17. Shimizu T, Fukagawa M, Kuroda T et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int 1997; 52: S239-S243.
18. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998; 54: 99-109.
19. Fukagawa M, Noda M, Shimizu T, Kurokawa K. Chronic progressive interstitial fibrosis in renal disease - are there novel pharmacologic approaches? Nephrol Dial Transplant 1999; 14: 2793-2795.
20. Iyer SN, Gurujeyalakshmi G, Siri SN. Effect of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291: 367-373.
21. Iyer SN, Gurujeyalakshmi G, Siri SN. Effect of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 289: 211-218.
22. Derynck R, Jarrett JA, Chen EY, Goeddel DV. The murine transforming growth factor-β precursor. J Biol Chem 1986; 261: 4377-4379.
23. Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 1988; 73: 459-468.
24. Fisher LW, Termine JD, Young MF. Deduced protein sequence of small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem 1989; 264: 4571-4576.
25. Fort P, Marty L, Piechaczyk M et al. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate dehydrogenase multigenic family. Nucl Acid Res 1985; 13: 1431-1442.
26. Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat. Transplantation 1990; 49: 445-452.
27. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
28. Khanna A, Li B, Stenzel KH, Suthanthiran M. Regulation of new DNA synthesis in mammalian cells by cyclosporine. Transplantation 1994; 57: 577-582.
29. Noble NA, Border WA. Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target? Semin Nephrol 1997; 17: 455-466.
30. Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, Border WA. Dietary protein restriction rapidly reduces transforming growth factor β1 expression in experimental glomerulonephritis. Proc Natl Acad Sci USA 1991; 88: 9765-9769.
31. Reyes AA, Pukerson ML, Karl I, Klahr S. Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 1992; 20: 168-176.
32. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001; 133: 687-694.
33. Khalil N, Corne S, Whitman C, Yacyshyn H. Plasmin regulates the activation of latent TGF-β secreted by alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol 1996; 15: 252-259.
34. Lee BS, Margolin SB, Nowak RA, Pirfenidone: A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998; 83: 219-223.
35. Armendariz-Borunda J, Katayama K, Seyer JM. Transcriptional mechanisms of type I collagen gene expression are differentially regulated by interleukin-1β, tumor necrosis factor α, and transforming growth factor β in to cells. J Biol Chem 1992; 267: 14316-14321.
36. Amento EP, Bhan AK, McCullagh KG, Krane SM. Influences of gamma interferon on synovial fibroblastlike cells, 1a induction and inhibition of collagen synthesis. J Clin Invest 1985; 76: 837-848.
37. Young B, Burdmann EA, Johnson RJ et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 1995; 48: 439-448.
38. Schegle ES, Mansoor JK, Giri S. Pirfenidone attenuates bleomycin induced changes in pulmonary function in hamsters. Proc Soc Exp Biol Med 1997; 216: 392-397.
39. Dosanjh AK, Wan B, Throndset W, Sherwood S, Morris RE. Pirfenidone: A novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplant Proc 1998; 30: 1910-1911.
40. Kaneko M, Inoue H, Nakazawa R et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) downregulation on cultured human synovial fibroblasts. Clin Exp Immunol 1998; 113: 72-76.
41. Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three dose bleomycin hamster model. Exp Lung Res 1998; 24: 119-132.